Cargando…
Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer
BACKGROUND: The objective of this study was to discover and to validate novel noninvasive biomarkers that distinguish between benign prostate hyperplasia (BPH) and localized prostate cancer (PCa), thereby helping to solve the diagnostic dilemma confronting clinicians who treat these patients. METHOD...
Autores principales: | Jedinak, Andrej, Curatolo, Adam, Zurakowski, David, Dillon, Simon, Bhasin, Manoj K, Libermann, Towia A, Roy, Roopali, Sachdev, Monisha, Loughlin, Kevin R, Moses, Marsha A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433087/ https://www.ncbi.nlm.nih.gov/pubmed/25884438 http://dx.doi.org/10.1186/s12885-015-1284-z |
Ejemplares similares
-
Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer
por: Jedinak, Andrej, et al.
Publicado: (2018) -
DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia
por: Kim, Stephanie S., et al.
Publicado: (2023) -
Benign Prostatic Hyperplasia
Publicado: (2015) -
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia
por: Kiebish, Michael A., et al.
Publicado: (2021) -
Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)